# Aurobindo Pharma Q1 profit rises 25% to Rs 1,032 crore 2026-08-06T17:45:52+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Aurobindo Pharma’s consolidated net profit rose 25.2% year on year to Rs 1,032 crore in the June quarter of FY27, The Hindu reports. Revenue from operations increased 16.3% to Rs 9,150 crore, with growth across its businesses. Formulations revenue rose 16.5% to Rs 8,101 crore. US formulations revenue grew 8.1% to Rs 3,770 crore, while Europe revenue climbed 25.6% to Rs 2,937 crore. API revenue increased 14.6% to Rs 1,049 crore. The company attributed US growth mainly to higher volumes and new launches, partly offset by the absence of transient product sales. Its board also approved the merger of Eugia Steriles and Eugia SEZ with Eugia Pharma Specialities. Aurobindo said the consolidation will cut administrative overheads and improve treasury management. All three units make injectable pharmaceutical products. ## Coverage - thehindu.com Tags: Aurobindo Pharma, mergers, pharmaceuticals, quarterly results Canonical: https://indianopinion.org/aurobindo-pharma-q1-profit-rises-25-to-rs-1032-crore/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/aurobindo-pharma-q1-profit-rises-25-to-rs-1032-crore/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.